ASH 2018 | Predictors of expansion/response to anti-BCMA CAR T-cells in R/R multiple myeloma
VJHemOnc is committed to improving our service to you
Thanks for your feedback, this will help us improve our content for you!
Adam Cohen, MD, of the University of Pennsylvania, Philadelphia, PA, discusses predictors of expansion and response following BCMA-directed CAR T-cell therapy in relapsed/refractory multiple myeloma. This expansion and response was correlated with a normal CD4:CD8 ratio and increased frequency of CD8+ T-cells with a CD45RO/CD27 phenotype, and not with tumor burden or other clinical characteristics. This has a number of implications for patient selection, timing of T-cell collection, and manufacturing processes. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
Get great new content delivered to your inboxSign up